Abstract
The coexistence of liver disease and osteopenic bone disease has been recognized for many years and is now the subject of increasing attention. Osteoporosis has been characterized well in patients with cholestatic liver disease, but new research suggests that osteopenia and osteoporosis may also be prevalent in patients with other chronic liver diseases. Although the precise mechanism of bone loss remains unclear, advances in treatment and prevention are bringing heightened awareness to this common problem.
Similar content being viewed by others
References and Recommended Reading
Hughes DE, Dai A, Tiffee JC, et al.: Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med 1996, 2:1132–1136.
Gallego-Rojo FJ, Gonzalez-Calvin JL, Munoz-Torres M, et al.: Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology 1998, 28:695–699.
Hattori N, Kurahachi H, Ikekubo K, et al.: Serum growth hormone-binding protein, insulin-like growth factor-I, and growth hormone in patients with liver cirrhosis. Metab Clin Exper 1992, 41:377–381.
Janes CH, Dickson ER, Okazaki R, et al.: Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995, 95:2581–2586.
Guanabens N, Pares A, Marinoso L, et al.: Factors influencing the development of metabolic bone disease in primary biliary cirrhosis. Am J Gastroenterol 1990, 85:1356–1362.
Hodgson S, Dickson E, Wahner H, et al.: Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 1985, 103:855–860.
Duarte MP, Farias ML, Coelho HS, et al.: Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease. J Gastroenterol Hepatol 2001, 16:1022–1027.
Lindor KD, Jorgensen RA, Tiegs RD, et al.: Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. J Hepatol 2000, 33:878–882.
Guanabens N, Pares A, Alvarez L, et al.: Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J Bone Miner Res 1998, 13:731–738.
Hay JE, Lindor KD, Wiesner RH, et al.: The metabolic bone disease of primary sclerosing cholangitis. Hepatology 1991, 14:257–261.
Matloff D, Kaplan M, Neer R, et al.: Osteoporsis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenteroogy 1981, 83:97–102.
Herlong H, Becker R, Maddrey W: Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterology 1982, 83:103–108.
Gong G, Stern H, Cheng S, et al.: The association of bone mineral density with vitamin d receptor gene polymorphisms. Osteoporos Int 1999, 9:55–64.
Pares A, Guanabens N, Alvarez L, et al.: Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology 2001, 33:554–560. This Spanish study of 61 women with primary biliary cirrhosis found no relationship between vitamin D receptor genotypes and bone mass.
Springer JE, Cole DE, Rubin LA, et al.: Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000, 118:145–51.
Guardiola J, Xiol X, Sallie R, et al.: Influence of the vitamin D receptor gene polymorphism on bone loss in men after liver transplantation. Ann Intern Med 1999, 131:752–755.
Hay JE: Vitamin D receptor polymorphism and posttransplantation bone loss. Liver Transpl 2001, 7:68–69.
Bell H, Raknerud N, Falch J, Haug E: Inappropriately low levels of gonadotrophins in amenorrhoeic women with alcoholic and non-alcoholic cirrhosis. Eur J Endocrinol 1995, 132:444–449.
Turner R: Skeletal response to alcohol. Alcohol Clin Exp Res 2000, 24:1693–1701.
Mitchison H, Malcolm A, Bassendine M, James O: Metabolic bone disease in primary biliary cirrhosis at presentation. Gastroenterology 1988, 94:463–470.
Porayko MK, Wiesner RH, Hay JE, et al.: Bone disease in liver transplant recipients: incidence, timing, and risk factors. Transplant Proc 1991, 23:1462–1465.
Eastell R, Dickson ER, Hodgson SF, et al.: Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology 1991, 14:296–300.
Camisasca M, Crosignani A, Battezzati P: Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 1994, 20:633–637.
Ormarsdottir S, Ljunggren O, Mallmin H, et al.: Low body mass index and use of corticosteroids, but not cholestasis, are risk factors for osteoporosis in patients with chronic liver disease. J Hepatol 1999, 31:84–90.
Angulo P, Therneau TM, Jorgensen A, et al.: Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J Hepatol 1998, 29:729–735.
Corazza G, Trevisani F, Di Stefano M, et al.: Early increase of bone resorption in patients with liver cirrhosis secondary to viral hepatitis. Dig Dis Sci 2000, 45:1392–1399. This Italian study confirmed that patients with viral cirrhosis have an increased rate of bone resorption when compared with healthy volunteers.
Chen C, Wang S, Jeng F, Lee S: Metabolic bone disease of liver cirrhosis: is it a parallel to the clinical severity of cirrhosis? J Gastroenterol Hepatol 1996, 11:417–421.
Solis-Herruzo J, Castellano G, Fernandez I, et al.: Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol 2000, 33:812–817.
Trautwein C, Possienke M, Schlitt H, et al.: Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am J Gastroenterol 2000, 95:2343–2351.
Carey EJ, Balan V, Kremers WK, Hay JE: Osteopenia and fracturing in hepatitis C and alcoholic liver disease: not just a cholestatic problem [abstract]. Gastroenterology 2002, 122:A531.
Peris P, Guanabens N, Pares A, et al.: Vertebral fractures and osteopenia in chronic alcoholic patients. Calcif Tissue Int 1995, 57:111–114.
Peris P, Pares A, Guanabens N, et al.: Reduced spinal and femoral bone mass and deranged bone mineral metabolism in chronic alcoholics. Alcohol Alcohol 1992, 27:619–625.
Rubin E, Caballeria J, Rodes J, Munoz J: Vertebral fractures and osteopenia in chronic alcoholic patients. Calcif Tissue Int 1995, 57:111–114.
Bikle DD, Stesin A, Halloran B, et al.: Alcohol-induced bone disease: relationship to age and parathyroid hormone levels. Alcohol Clin Exp Res 1993, 17:690–695.
Schnitzler CM, Solomon L: Bone changes after alcohol abuse. South Afr Med J 1984, 66:730–734.
Siris E, Miller P, Barrett-Connor E, et al.: Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. JAMA 2001, 286:2815–2822.
Felson D, Zhang Y, Hannan M, et al.: Alcohol intake and bone mineral density in elderly men and women. The Framingham Study. Am J Epidemiol 1995, 142:485–492.
Santolaria F, Gonzalez-Reimers E, et al.: Osteopenia assessed by body composition analysis is related to malnutrition in alcoholic patients. Alcohol 2000, 22:147–157.
Epstein O, Kato Y, Dick R, Sherlock S: Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis. Am J Clin Nutr 1982, 36:426–430.
Matloff DS, Kaplan MM, Neer RM, et al.: Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 1982, 83:97–102.
Crippin J, Jorgensen R, Dickson E, Lindor K: Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 1994, 89:47–50.
Collier JD, Ninkovic M, Compston JE: Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002, 50:1–9. A brief review of the literature with consensus guidelines on current management of osteoporosis in chronic liver disease.
Shiomi S, Masaki K, Habu D, et al.: Calcitriol for bone disease in patients with cirrhosis of the liver. J Gastroenterol Hepatol 1999, 14:547–552.
Olsson R, Mattsson L, Obrant K, Mellstrom D: Estrogenprogestogen therapy for low bone mineral density in primary biliary cirrhosis. Liver 1999, 19:188–192.
Floreani A, Zappala F, Fries W, et al.: A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. J Clin Gastroenterol 1997, 24:239–244.
Hay J, Malinchoc M, Dickson R: A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 2001, 34:292–298. This randomized, controlled trial of 63 patients undergoing liver transplantation for cholestatic liver disease established the lack of benefit of calcitonin on bone density or fracture.
Wolfhagen F, van Buuren H, den Ouden J, et al.: Cyclical etidronate in the prevention of bone los in corticosteroidtreated primary biliary cirrhosis: a prospective, controlled pilot study. J Hepatol 1997, 26:325–330.
Guanabens N, Farrerons J, Perez-Edo L, et al.: Cyclical etidronate versus sodium fluoride in established postmenopausal osteoporosis: a randomized 3 year trial. Bone 2000, 27:123–128.
Pares A, Guanabens N, Ros I, et al.: Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis [abstract]. Hepatology 1999, 30:472A.
Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434–1441.
Guanabens N, Pares A, del Rio L, et al.: Sodium fluoride prevents bone loss in primary biliary cirrhosis. J Hepatol 1992, 15:345–349.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carey, E., Balan, V. Metabolic bone disease in patients with liver disease. Curr Gastroenterol Rep 5, 71–77 (2003). https://doi.org/10.1007/s11894-003-0012-z
Issue Date:
DOI: https://doi.org/10.1007/s11894-003-0012-z